Early multidrug resistance, defined by changes in intracellular doxorubicin distribution, independent of P-glycoprotein. by Schuurhuis, G. J. et al.
Br. J. Cancer (1991), 64, 857-861
1991
Early multidrug resistance, defined by changes in intracellular doxorubicin
distribution, independent of P-glycoprotein
G.J. Schuurhuis', H.J. Broxterman', J.H.M. de Lange2, H.M. Pinedo"3, T.H.M. van
Heijningen', C.M. Kuiperl, G.L. Scheffer2, R.J. Scheper2, C.K. van Kalken', J.P.A. Baak2 & J.
Lankelmal
Departments of'Medical Oncology and2Pathology, de Boelelaan 1117, 1081 HVAmsterdam; 3Netherlands Cancer Institute,
Amsterdam, The Netherlands.
Summary Resistance to multiple antitumour drugs, mostly antibiotics or alkaloids, has been associated with
a cellular plasma membrane P-glycoprotein (Pgp), causing energy-dependent transport of drugs out of cells.
However, in many common chemotherapy resistant human cancers there is no overexpression of Pgp, which
could explain drug resistance. In order to characterise early steps in multidrug resistance we have derived a
series of P-glycoprotein-positive (Pgp/+) and P-glycoprotein-negative (Pgp/-) multidrug resistant cell lines,
from a human non-small cell lung cancer cell line, SW-1573, by stepwise selection with increasing concentra-
tions of doxorubicin. These cells were exposed to doxorubicin and its fluorescence in nucleus (N) and
cytoplasm (C) was quantified with laserscan microscopy and image analysis. The fluorescence N/C ratio in
parent cells was 3.8 and decreased both in Pgp/+ and Pgp/- cells with increasing selection pressure to
1.2-2.6 for cells with a resistance factor of 7-17. N/C ratios could be restored partly with verapamil only in
Pgp/+ cells. N/C ratio measurements may define a general Pgp-independent type of defense of mammalian
cells against certain anticancer agents which may precede Pgp expression in early doxorubicin resistance.
The development of resistance of human cancers to potent
anticancer agents has been classically ascribed to the selection
and outgrowth of pre-existing or newly occurring subpopula-
tions of resistant tumour cells (Carl, 1989; Coldman & Goldie,
1985; Skipper, 1986). Great progress in the understanding of
the mechanism of one type of in vitro derived resistance, the
so-called multidrug resistance (MDR), was recently obtained
from the successful cloning and transfection of the mdrl
gene, which codes for a 170kDa plasmamembrane protein,
called P-glycoprotein (Pgp) (Gottesman & Pastan, 1988;
Hammond et al., 1989; Juranka et al., 1989; Lincke et al.,
1990). The role of this glycoprotein was elucidated by study-
ing the phenotype ofcell lines, transfected with mdrl (Gottes-
man & Pastan, 1989; Hammond et al., 1989; Juranka et al.,
1989; Lincke et al., 1990) or selected in vitro for resistance to
anticancer agents, such as anthracyclines and vinca alkaloids,
colchicine and actinomycin D (Biedler et al., 1988; Bradley et
al., 1988). Thus Pgp was proven to confer multidrug resis-
tance. Further it was proposed that Pgp functions as a
plasma membrane pump for several classes of lipophilic
drugs. Evidence for this was based on the predicted amino
acid sequence of Pgp, which contained two consensus ATP
binding sites, and on the demonstration of ATP-dependent
drug binding to Pgp and energy-dependent drug efflux from
Pgp/+ cells (Broxterman et al., 1988; Choi et al., 1988; Gros
et al., 1986). However, it has been shown that in some
Pgp/+ cells with high levels of doxorubicin resistance the net
change in cellular accumulation of drug was relatively
modest, which was taken as argument against an important
role of such a drug export protein in the resistance mecha-
nism in these cells (Siegfried et al., 1983). Recently we
showed that in the Pgp/+ cells 2780AD and CHRC5, the
resistance to doxorubicin could be quantitatively accounted
for, when, in addition to doxorubicin accumulation, the
distribution of doxorubicin between nuclear sites and cyto-
plasmic localisations was taken into consideration (Schuur-
huis et al., 1989). The data suggested that these Pgp/+ cells
had developed a resistance mechanism characterised by a
decrease in net cellular doxorubicin accumulation, including
the nuclear target sites, while accumulation in cytoplasmic
structures was relatively unaffected.
We have now investigated whether such a defence mechan-
ism of mammalian cells against certain types of anticancer
agents is necessarily dependent on Pgp overexpression and
we have therefore especially focussed on low level resistant
cells. Hereto we used two series of variants selected by
doxorubicin exposure from the human non-small cell lung
cancer cell line, SW-1573, which both displayed multidrug
resistance.
Materials and methods
Cells and cell culture
The human non-small cell lung cancer cell line was obtained
from Dr H. Joenje (Department of Anthropogenetics, Free
University, Amsterdam; Keizer et al., 1989) and was cultured
in Dulbecco's modified Eagle's medium + 7.5-10% foetal
calf serum (GIBCO Europe, Paisley, Scotland). The resistant
sublines were derived by continuous exposure to increasing
doxorubicin concentrations: e.g. 2R50 (2R80 etc) means that
these cells were continuously cultured in 50 (80 etc) nM
doxorubicin, until they were harvested 7-14 days before the
experiments by short trypsinisation. There was no significant
difference in cell size between all the SW-1573 sublines (dia-
meter SW-1573: 16.2 ± 1.2 gsm in nine experiments). Cell
cycle distribution as measured with flow cytometry (GI, S
and G2 + M phase, resp., expressed as % of total number of
cells and determined in two independent experiments) was as
follows. SW-1573: 54, 37 and 9, resp.; SW-1573/2R50: 59,33
and 9, resp.; SW-1573/2R120: 62, 20 and 19, resp.; SW-1573/
4R50: 41, 40 and 19, resp.; SW-1573/4R120: 54, 28 and 18,
resp. Cell doubling times were 22 ± 1 (SW-1573), 32 ± 3
(SW-1573/2R50), 38 ± 3 (SW-1573/2R120), 43 ± 5 (SW-1573/
2R160), 26 ± 1 (SW-1573/4R50) and 28 ± 2 (SW-1573/4R120),
determined in 3-5 independent experiments (M ± s.d.).
Drug cytotoxicity
Doxorubicin resistance factor (RF) and dose-modifying fac-
tor (DMF) were calculated from 50% cell-growth inhibitory
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concentrations of doxorubicin (IC") determined in a cell
proliferation assay; IC50 of SW-1573 cells was 0.12 ± 0.02gM
(mean ± s.d. of 5 exp., 2 h drug exposure in a waterbath at
37°C in culture medium lacking NaHCO3 but containing
20 mM HEPES). After 2 h exposure to doxorubicin and
32jM verapamil (for DMF), the cell culture medium was
refreshed and after another 4 h with or without verapamil in
the same medium the cells were allowed to grow in NaHCO3
containing medium for three cell doubling-times, again in
the presence of 32 gM verapamil for DMF determinations
(Schuurhuis et al., 1987). The 2 h exposure was carried out in
medium lacking NaHCO3 in order to be able to compare the
cytotoxicity data directly with drug accumulation and N/C
ratio measurements (see below). The IC50 value for SW-1573
cells was lower (factor 2) in medium lacking NaHCO3 than
in growth medium but no major differences in resistance
factors were found when the two media were compared.
Resistance factors for the other drugs were determined in
a cell proliferation assay by a continuous incubation with
drugs as described (Broxterman et al., 1989; Mosman, 1983).
A concentration of 32tLM verapamil was used in order to
obtain maximal effects on doxorubicin accumulation, cyto-
toxicity and intracellular drug distribution, since in case low
level MDR cells are used these parameters do not differ
much from those in sensitive cells. Previously dose-dependent
effects of verapamil on these parameters have been shown
(Schuurhuis et al., 1987, 1989, 1990).
Drug accumulation
Doxorubicin accumulation and accumulation-enhancement
factor by co-incubation with 32JM verapamil (AEF) were
determined by exposure of adhered cells to 0.5 fLM [14C]-
doxorubicin (2 h, 37°C) in culture medium lacking NaHCO3,
three rapid cold washes and subsequent trypsinisation of
the cells; further procedures were essentially as described
(Schuurhuis et al., 1987).
Flow cytometry
For quantification of Pgp, 106 unfixed cells were incubated
with the monoclonal antibody MRK-16 (4Agml-') or an
irrelevant mouse IgG (51igml-) for 1 h in a volume of
2001l at 20°C. Samples were washed three times with phos-
phate buffered saline + 1% bovine serum albumin (PBS-BSA)
and incubated with 100gl rabbit-antimouse IgG-fluores-
ceinisothiocyanaat (100lg ml1'), DAKO immunoglobulins,
Copenhagen, Denmark) for 45 min at 20°C. After washing
the cells three times with PBS-BSA, the cells were resus-




Cell line RF (dox) (32jom Vp) (% ofSW-1573) (32gMVp)
SW-1573 1 1.6±0.3d 100 1.16±0.09c
4R50 7.7±3.8 7.3±1.4d 12.2±0.5d 5.9 ±0.lc
4R80 10.0± 1.2 12.8± 1.4d 10.2±0.2d 7.4 ±0.7d
4R120 13.2± 1.9 lo.o±o.9d 10.9±l.od 5.2 ±0.4d
4R160 16.7±0 16.1±0.9d 7.1±0.2d 10.0 ± .lC
2R50c 6.9±0.3 2.5±0.1c 34.0±6.od 1.3 ±0.1
2R80F 9.4±2.0 5.5±1.4d 35.4±2.5d 1.3 ±0.2
2R120c 11.1±2.8 6.3± 0.4d 41.9±8.od 1.4 ±0.2
2R160 63 ± 12 17.2± 1.3d 4.7±od 9.3 ± 1.7d
aDMF, dose modifying factor = IC50 minusVp/IC50 plus Vp. bAEF,
accumulation enhancement factor = drug accumulation plus Vp/drug
accumulation minusVp. Data aremeans±s.d. of2-3experimentseach
performed at least in duplicate (cytotoxicity) or triplicate (accumula-
tion). c,d Significantly different from I (DMF), from SW-1573 (-Vp)
levels (fourth column) or from accumulation -Vp (fifth column): cP<0.02; dP<0.01 (Student's t-test). enon-Pgp cell lines, as measured
with RNAase protection assay (Baas etal., 1990; Zinn et al., 1983). Vp,
verapamil.
pended in 500 ttl PBS-BSA and fluorescence was measured
with a FACSTAR Plus, Becton Dickinson Medical Systems
(Sharon, Ma).
Determination ofN/C doxorubicinfluorescence ratios
Trypsinised cells were allowed to adhere on tissue culture
petri dishes (Costar, Cambridge, Ma) for 24h. Cells were
incubated with doxorubicin for 1 h under the same condi-
tions as described for drug accumulation and cytotoxicity
experiments in Table I and quickly washed with PBS to
reduce background fluorescence. PBS was lacking glucose to
prevent drug efflux and redistribution. Dox concentrations
were chosen to obtain equal net cellular drug amounts in all
cell lines (4pM in SW-1573 cells). Thirty to fifty cells were
recorded for each treatment using laserscan microscopy and
fluorescence ratios were quantified by delineating nuclei and
cytoplasms interactively using digital image analysis as des-
cribed (Schuurhuis et al., 1989).
Determination ofthe ratio intercalateddoxorubicin/
non-intercalatedfluorescent doxorubicin
The ratios of intercalated doxorubicin vs non-intercalated
fluorescent doxorubicin were determined as described (Lan- kelma et al., 1990). SW-1573 and SW-1573/2R160 cells were
loaded for 1 h at 37°C with 4 and 20gM doxorubicin, respec- tively, in order to obtain about equal intracellular drug
amounts.
RNAaseprotection assay
Ten jg RNA samples were hybridised with a 32P-labelled 301
nucleotide human mdrl cDNA specific probe, obtained from
F. Baas, Neth. Cancer Inst., and analysed by RNAase pro- tection assay essentially as described (Baas et al., 1990; Zinn
et al., 1983). A T-actin probe was used to control for equal
amounts of analysed RNA.
Results and discussion
Two separate series of resistant cells were selected by con-
tinuous exposure to 50, 80, 120 and 160 nM doxorubicin.
The cross-resistance pattern of the 2R series has recently been described (Baas et al., 1990; Kuiper et al., 1990); it was
shown that all sublines from this series had a decreased
doxorubicin and vincristine accumulation, while Pgp expres- sion, which was detectable with a sensitive RNAase protec- tion assay in the parent cell line, was lost during an early selection step, but reappeared, strongly overexpressed, at a
later selection step (Baas et al., 1990; Kuiper et al., 1990). In
Table II Cross-resistance in SW-1573 variants
RF RF RF RF
Cell line (dauno) (vincr) (gramD) (etoposide) pgpa
SW-1573 1 1 1 1 1.08±0.05 4R50 3.0±1.3 213± 80 161±53 6.6±2.0 21.4 ±4.2 4R80 3.4± 1.6 222± 76 185±70 5.0±2.1 37.6 ±4.3 4R120 4.9±3.5 299± 55 149±45 5.2± 1.2 20.8 ±2.4 A Yk I -If I 4RI60 6.6±3.7 22.4 ±5.4 2RSOb 3.3±0.4 5.8± 1.1 3.2± 1.1 14± 6 1.10±0.15 2R80b 5.9±1.6 16± 3 3.1 (n= 1) 21±17 ND 2R120b 3.7±0.1 17± 3 2.3± 1.7 45± 13 1.02±0 2R160 35±9 480± 170 146±33 120±36 20.4 ±8.2
Resistance factors (RF) were determined in a continuous incubation
assaywithdrug asdescribed(Broxterman etal., 1989; Mosmann, 1983). Data are means± s.d. from 3-4 separate experiments. The RF data for daunorubicin, vincristine, gramicidin D and etoposide for the 2R series
are from Kuiper et al., 1990 and are shown for comparison. aData are given as mean fluorescence ofMRK-16, divided by mean fluorescence IgG (mean± s.d. of2 experiments). Fluorescence ratio for 2780AD cells (Schuurhuis et al., 1987) was 37 (mean of seven experiments). bpgp negative cell lines (see Table I). ND, not determined.




which was more prominent, however, in the 4R series (Table
I). Especially in the 2R series the accumulation defect would
not be sufficient to fully account for the observed resistance
factors. Doxorubicin accumulation, like doxorubicin resis-
tance, could be modulated more effectively in the Pgp/+ cells
(Table I). Thus, while interaction of verapamil with Pgp
seems to allow an effective modulation of doxorubicin resis-
tance and accumulation, it does not prove that doxorubicin
resistance and impairment of accumulation in these Pgp/+
cells is directly caused by Pgp.
We have shown before by a quantitative approach using
laserscan microscopy and image analysis that a decrease
in doxorubicin fluorescence nucleus/cytoplasm (N/C) ratio
could be measured in the low level mdr Pgp/+ cell line
8226/dox 4 (Broxterman et al., 1990). Those data suggested a
correlation of doxorubicin fluorescence N/C ratio with Pgp
expression. The present SW-1573 experimental system allow-
ed us to study the doxorubicin fluorescence N/C ratio's in
cells with increasing levels of multidrug resistance in Pgp/+
as well as Pgp/- cells, derived from the same parent cells.
Figure 2 shows a decrease in N/C ratio with increasing
selection pressure in Pgp/+ as well as in Pgp/- cells. Inter-
estingly, N/C ratios were slightly lower in Pgp/- cells com-
pared to Pgp/+ cells at the same levels of resistance, while
on the other hand doxorubicin accumulation was less in the
Pgp/+ cells (Table I). This suggests that the relative contri-
bution of decreased drug accumulation and altered drug
4.0
Actin
Figure 1 mdrl overexpression is an all or non phenomenon in
the present cell lines. The RNAase protection assay was carried
out as described under Materials and methods. From left to right
bands corresponding to RNA from SW-1573, 4R50, 4R80, 4R120
and 4R160 are shown. The parent SW-1573 cells have a just
detectable signal, which varies somewhat with proliferation state
of the cells (Baas et al., 1990). It was shown before that the
similarity in intensity was not due to saturation phenomena
because that a further increase of intensity occurs with a further
increase of drug selection pressure (Baas et al., 1990).
a separate selection with doxorubicin, the 4R series was
derived (Tables I and II) which appeared to have overexpres-
sion of Pgp from the first selection step on, as determined at
protein level with the monoclonal antibody MRK-16 (Table
II) and with a RNAase protection assay using a mdrl specific
probe (Figure 1). Remarkably the 4R50, 4R120, 4R160 as
well as the 2R160 cells have similar amounts of Pgp, while
the 4R80 cells for unknown reasons have higher amounts
(Table II). In separate experiments it was shown that cells
with a higher degree of resistance (2780AD, Schuurhuis et al.,
1987) have a higher amount of Pgp (see legends of Table II),
indicating non-saturability of the method used. Both the 2R
and 4R series display a MDR-like phenotype with, relative to
doxorubicin and daunorubicin resistance (Tables I and II),
high vincristine and gramicidin D resistance in Pgp/+ cells
and high etoposide resistance in Pgp/- cells (Table II).
Doxorubicin resistance could be modulated by coincubation
with verapamil in 4R.Pgp/+ cells to a large extent (Table I).
In 2R.Pgp/- cells, however, the resistance modulation with
verapamil was less effective (Table I). Both the 2R and 4R



















Figure 2 Doxorubicin fluorescence nucleus/cytoplasm (N/C)
ratios as a function of doxorubicin resistance in Pgp/+ and
Pgp/- cells. Fluorescence N/C ratios were determined as des-
cribed under Materials and methods. Data are from three inde-
pendent experiments each performed in duplicate (means±s.d.).
Table III Effect of verapamil on doxorubicin fluorescence ratios in
SW-1573 variants
Cell line N/C N/C ( + verapamil)
SW-1573 3.77±0.18 3.87±0.44 [1.0]
4R50 2.60±+0.18b 3.27±0.25c [1.3]
4R80 1.89±0.37b 4.02±0.18e [2.1]
4R120 2.02±0.17b 3.04±0.10d [1.5]
4R160 1.16±0.24b 2.61 ±0.llc [2.3]
2R50a 2.18+±0.16b 1.70±0.03 [0.8]
2R80a 1.72±0.24b 1.81 ±0.23 [1.1]
2R120a 1.75±+0.13b 1.77±0.37 [1.0]
2R160 0.67±0.12b 2.39±0.64e [3.6]
N/C ratios(doxorubicin fluorescence innucleus/doxorubicinfluores-
cence in cytoplasm) were measured as described for Figure 2. a pgp
negativecell lines. bSignificantlydifferent from 3.77 (P<0.01, Student's
t-test). cdeSignificantly different from N/C ratios minus verapamil:
cP<0.05; dp<0.02; 'P<0.01. Values in brackets represent factor
increase of N/C ratios by verapamil. Data are from 2-6 independent
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distribution to the resistance phenotype may differ depending
on the presence of Pgp. The fact that 4R160 cells have a
lower N/C ratio than e.g. 4R50 cells, despite similar amounts
of Pgp, indicates that the non-Pgp resistance mechanism
might also be present in the 4R cells. However, it cannot be
excluded that the high resistance to VP-16 in Pgp/- cells
would be caused in part by additional changes such as an
altered topoisomerase II activity (Baas et al., 1990).
Again, like for doxorubicin accumulation, for an effective
modulation of doxorubicin fluorescence N/C ratio by
verapamil the presence of Pgp seems to be a prerequisite
(Table III, compare e.g. 2R120 with 4R120 cells). Remark-
ably, verapamil-induced changes in accumulation (Table I)
together with changes in N/C ratios (Table III) can account
for resistance modulation (DMF, Table I) in Pgp/+ cells but
not in Pgp/- cells, which leaves the possibility of additional
actions ofverapamil which affect doxorubicin cytotoxicity. In
the 4R series the 4R80 cells show a somewhat exceptional
behaviour: the amount of Pgp as estimated with flow cyto-
metry is higher than in the other 4R cells (Table II). In line
with this stimulation of doxorubicin accumulation as well as
reversal of resistance by verapamil was more prominent in
the 4R80 cells (Table I). Also the N/C ratio in 4R80 cells was
relatively low, while its modification with verapamil was
relatively high (Table III).
In this study doxorubicin fluorescence N/C ratios are used
operationally to probe mechanisms ofdrug resistance, related
to changes in intracellular drug distribution. These ratios as
such do not reflect the actual concentrations of doxorubicin
in each compartment, since they do not take into account the
quenching of doxorubicin fluorescence at several different
localisations of the drug: quenching of doxorubicin fluore-
scence due to DNA intercalation has been estimated at 95%
(Chaires et al., 1982), while cytoplasmic fluorescence may be
largely unaffected (Budge & Tritton, 1985; Tarasiuk et al.,
1989). We have used an independent technique to show that
N/C ratio changes reflect changes in the actual compartmen-
tal amounts of doxorubicin. With this technique the ratio
intercalated drug/non-intercalated fluorescent drug can be
measured (Lankelma et al., 1990). It was found that this
ratio was 4.2 ± 0.6 in SW-1573 cells and 1.2 ± 0.2 in SW-
1573/2R160 cells (M ± s.e.m. of two independent experi-
ments). N/C ratio changes might also be found if certain
drug binding sites in the cell are saturated at the relatively
high drug concentrations which were used in the fluorescence
assays. This is unlikely, however, since N/C ratios were
shown to be independent of doxorubicin concentrations in
the medium (J.H.M. de Lange, N.W. Schipper, G.J. Schuur-
huis et al., manuscript submitted).
The molecular mechanism(s) responsible for the induction
of decreases in doxorubicin N/C ratio are not yet known; in
the SW-1573 cell lines the presence of Pgp is not required for
this decrease to occur. One explanation would be the
presence of a pump protein present at vesicular membranes
oriented to pump drug inside such vesicles. However, in the
case of Pgp, the antigenic determinant of MRK-16 could be
detected only on the Golgi stack but not in other vesicles
(Willingham et al., 1987). Moreover, similar amounts of Pgp,
as estimated with MRK-16 binding, do not seem to correlate
with resistance factor or N/C ratios (compare e.g. 2R160 and
4R160 cells in the Tables I-III). Thus, even after the induc-
tion of Pgp overexpression, the early, non-Pgp mediated
mechanism, may still be operative. Since cytoplasmic pH was
elevated in some resistant SW-1573 isolates, compared to
SW-1573 parent cells as measured in medium without bicar-
bonate (Keizer & Joenje, 1989), one possibility to be con-
sidered is that anthracyclines are forced to accumulate to a
higher extent in an acidic vesicular compartment in the cell
(Beck, 1987; Keizer et al., 1989; Sehested et al., 1987). Since
even in steady-state the 2R.Pgp/- cells accumulated less
doxorubicin (Table I) or vincristine (Kuiper et al., 1990), an
active extrusion process could be present. Active drug ext-
rusion processes for different types of drugs, not related to
Pgp overexpression, have in fact been reported recently
(Henderson & Tsuji, 1990; Hindenburg et al., 1989; McGrath
et al., 1989a,b). In such highly resistant cells anthracycline
resistance could also be related to differences in drug binding
to nuclear and cytoplasmic bindings sites (Hindenburg et al.,
1989). Since different independently selected, lowly resistant
isolates from SW-1573 cells showed the Pgp/- multidrug
resistance (Baas et al., 1990), which now has been shown to
be related to decreased doxorubicin N/C ratio's, a mutation
in one gene product could be responsible for the observed
resistance pattern in Pgp/- cells. The remarkably low resis-
tance factors of 4R160 compared to 2R160 for both anthra-
cyclines and etoposide, despite a similar Pgp expression fur-
ther suggests that such a mechanism still prevails in the
resistance of 2R160 Pgp/+ cells for these drugs. The com-
bined measurement of doxorubicin accumulation and fluore-
scence N/C ratio's in tumour cells, isolated directly from
patient's tumours would allow to investigate the role of drug
transport resistance in failure of chemotherapy. Further,
applying immunohistochemical staining techniques after N/C
ratio measurements would allow a direct comparison offunc-
tional changes (reflected by N/C ratio changes) and the
presence of resistance-related antigenic determinants (e.g
Pgp) in individual cells.
This study was supported by the Dutch Cancer Society (grant IKA-
VU 88-22) and by a grant from the Bristol-Myers Squibb Company.
H.J.B. is a fellow of the Royal Netherlands Academy of Arts and
Sciences. We thank H.S Miilder for determination of the ratios
intercalated drug/non-intercalated drug. Dr P. Borst and Dr F. Baas
are acknowledged for their stimulating discussions of this work. We
thank Dr T. Tsuruo for the generous supply of MRK-16.
References
BAAS, F., JONGSMA, A.P.M., BROXTERMAN, H.J. & 7 others (1990).
Non-P-glycoprotein mediated mechanism for multidrug resistance
precedes P-glycoprotein expression during in vitro selection for
doxorubicin resistance in a human lung cancer cell line. Cancer
Res., 50, 5392.
BECK, W.T. (1987). The cell biology of multiple drug resistance.
Biochem. Pharmacol., 36, 2879.
BIEDLER, J.L., CHANG, T-d., SCOTTO, K.W., MELERA, P.W. & SPEN-
GLER, B.A. (1988). Chromosomal organization of amplified genes
in multidrug-resistant Chinese hamster cells. Cancer Res., 48,
3179.
BRADLEY, G., JURANKA, P.F. & LING, V. (1988). Mechanism of
multidrug resistance. Biochim. Biophys. Acta, 948, 87.
BROXTERMAN, H.J., PINEDO, H.M., KUIPER, C.M., KAPTEIN, L.C.M.,
SCHUURHUIS, G.J. & LANKELMA, J. (1988). Induction of vera-
pamil of a rapid increase in ATP consumption in multidrug-
resistant tumor cells. FASEB J., 2, 2278.
BROXTERMAN, H.J., PINEDO, H.M., KUIPER, C.M. & 7 others (1989).
Immunohistochemical detection of P-glycoprotein in human
tumour cells with a low degree of drug resistance. Int. J. Cancer,
43, 340.
BROXTERMAN, H.J., SCHUURHUIS, G.J., LANKELMA, J., BAAK,
J.P.A. & PINEDO, H.M. (1990). Towards functional screening for
multidrug resistant cells in human malignancies. In Drug Resis-
tance: Mechanisms and Reversal, Mihich, E. (ed.), p. 309, John
Libbey CIC: Roma.
BUDGE, T.G. & TRITTON, T.R. (1985). Location and dynamics of
anthracyclines bound to unilamellar phosphatidylcholine vesicles.
Biochemistry, 24, 5972.
CARL, J. (1989). Drug-resistance patterns assessed from tumor
marker analysis. J. Natl Cancer Inst., 81, 1631.INTRACELLULAR DRUG DISTRIBUTION IN MULTIDRUG RESISTANCE 861
CHAIRES, J.B., DATTAGUPTA, N. & CROTHERS, D.M. (1982). Studies
on interaction of anthracycline antibiotics and deoxyribonucleic
acid: equilibrium binding studies on interaction of daunomycin
with deoxyribonucleic acid. Biochemistry, 21, 3933.
CHOI, K., CHEN, C-j., KRIEGLER, M. & RONINSON, I.B. (1988). An
altered pattern of cross-resistance in multidrug-resistant human
cells results from spontaneous mutations in the mdrl (P-glyco-
protein) gene. Cell, 53, 519.
COLDMAN, A.J. & GOLDIE, J.H. (1985). Role ofmathematical model-
ing in protocol formulation in cancer chemotherapy. Cancer
Treat. Rep., 69, 1041.
GOTTESMAN, M.M. & PASTAN, I. (1988). Resistance to multiple
chemotherapeutic agents in human cancer cells. Tr. Pharmacol.
Sci., 9, 54.
GROS, P., CROOP, J. & HOUSMAN, D. (1986). Mammalian multidrug
resistance gene: complete cDNA sequence indicates strong homo-
logy to bacterial transport proteins. Cell, 47, 371.
HAMMON, J.R., JOHNSTONE, R.M. & GROS, P. (1989). Enhanced
efflux of [3H] vinblastine from Chinese hamster ovary cells trans-
fected with a full-length complementary DNA clone for the mdrl
gene. Cancer Res., 49, 3867.
HENDERSON, G.B. & TSUJI, J.M. (1990). Identification ofcholate as a
shared substrate for the unidirectional efflux systems for metro-
trexate in L1210 mouse cells. Biochem. Biophys. Acta, 1051, 60.
HINDENBURG, A.A., GERVASONI, J.E., KRISHNA, S. & 6 others
(1989). Intracellular distribution and pharmacokinetics of dauno-
rubicin in anthracycline-sensitive and -resistant HL-60 cells.
Cancer Res., 49, 4607.
JURANKA, P.F., ZASTAWNY, R.L. & LING, V. (1989). P-glycoprotein:
multidrug-resistance and a superfamily of membrane-associated
transport proteins. FASEB J., 3, 2583.
KEIZER, H.G. & JOENJE, H. (1989). Increased cytosolic pH in multi-
drug-resistant human lung tumor cells: effect of verapamil. J.
Nat! Cancer Inst., 81, 706.
KEIZER, H.G., SCHUURHUIS, G.J., BROXTERMAN, H.J. & 5 others
(1989). Correlation of multidrug resistance with decreased drug
accumulation, altered subcellular drug distribution, and increased
P-glycoprotein expression in cultured SW-1573 human lung
tumor cells. Cancer Res., 49, 2988.
KUIPER, C.M., BROXTERMAN, H.J., BAAS, F. & 5 others (1990).
Drug transport variants without P-glycoprotein overexpression
from a human squamous lung cancer cell line after selection with
doxorubicin. J. Cell Pharmacol., 1, 35.
LANKELMA, J., MULDER, H.S., VAN MOURIK, F., WONG FONG
SANG, H.W., KRAAYENHOF, R. & VAN GRONDELLE, R. (1991)
Cellular daunomycin fluorescence in multidrug resistant 2780AD
cells and its relation to cellular drug localisation. Biochim.
Biophys. Acta, 1093, 147.
LINCKE, C.R., VAN DER BLIEK, A.M., SCHUURHUIS, G.J., VAN DER
VELDE-KOERTS, T., SMIT, J.J.M. & BORST, P. (1990). Multidrug
resistance phenotype of human BRO melanoma cells transfected
with a wild-type human mdrl complementary DNA. Cancer Res.,
50, 1779.
MCGRATH, T., LATOUD, C., ARNOLD, S.T., SAFA, A.R., FELSTED,
R.L. & CENTER, M.S. (1989a). Mechanisms of multidrug resis-
tance in HL60 cells. Analysis of resistance associated membrane
proteins and levels of mdr gene expression. Biochem. Pharmacol.,
38, 3611.
MCGRATH, T., MARQUARDT, D. & CENTRE, M.S. (1989b). Multiple
mechanisms of adriamycin resistance in the human leukemia cell
line CCRF-CEM. Biochem. Pharmacol., 38, 497.
MOSMANN, T. (1983). Rapid colometric assay for cellular growth
and survival: application to proliferation and cytotoxicity assays.
J. Immunol. Meth., 65, 55.
SCHUURHUIS, G.J., BROXTERMAN, H.J., CERVANTES, A. & 5 others
(1989). Quantitative determination of factors contributing to
doxorubicin resistance in multidrug-resistant cells. J. Natl Cancer
Inst., 81, 1887.
SCHUURHUIS, G.J., BROXTERMAN, H.J., PINEDO, H.M. & 5 others
(1990). The polyoxyethylene castor oil Cremophor EL modifies
multidrug resistance. Br. J. Cancer, 62, 591.
SCHUURHUIS, G.J., BROXTERMAN, H.J., VAN DER HOEVEN, J.J.M.,
PINEDO, H.M. & LANKELMA, J. (1987). Potentiation of doxo-
rubicin cytotoxicity by the calcium antagonist bepridil in anthra-
cycline-resistant and -sensitive cell lines. A comparison with
verapamil. Cancer Chemother. Pharmacol., 20, 285.
SEHESTED, M., SKOVSGAARD, T., VAN DEURS, B. & WINTER-NIEL-
SEN, H. (1987). Increased plasma membrane traffic in dauno-
rubicin resistant P388 leukaemic cells. Br. J. Cancer, 56, 747.
SIEGFRIED, J.M., TRITTON, J.R. & SARTORELLI, A.C. (1983). Com-
parison of anthracycline concentrations in SI80 cell lines of
varying sensitivity. Eur. J. Cancer Clin. Oncol., 19, 1133.
SKIPPER, H.E. (1986). On mathematical modeling of critical variables
in cancer treatment. Goals: better understanding of the past and
better planning in the future. Bull. Math. Biol., 48, 253.
TARASIUK, J., FREZARD, F., GARNIER-SUILLEROT, A. & GATTEG-
NO, L. (1989). Anthracycline incorporation in human lympho-
cytes. Kinetics of uptake and nuclear concentration. Biochim.
Biophys. Acta, 1013, 109.
WILLINGHAM, M.C., RICHERT, N.D., CORNWELL, M.M. & 4 others
(1987). Immunocytochemical localization of P170 at the plasma
membrane of multidrug-resistant human cells. J. Histochem.
Cytochem., 35, 1451.
ZINN, K., DIMAIO, D. & MANIATIS, T. (1983). Identification of two
distinct regulatory regions adjacent to the human b-interferon
gene. Cell, 34, 865.